CDKN2A and neoplasm: Examples include: poorer survival in tumors with gains of both 7p15-21 and 17q22-qter22; increased risk of tumor recurrence with 8q gain20; poorer survival with 8p23-p12 gain21; and poorer prognosis in presence of the CDKN2A/B deletion.23